Sirtuin 3
SIRT3proteinSIRT3 modulates macrophage oxidative stress and inflammation, with reduced activity contributing to plaque destabilization and Type 1 MI risk.
Pathway placement
Cascade stepPlaque inflammation
Confidencemedium
RationaleMitochondrial deacetylase regulating macrophage oxidative stress and inflammatory activation in plaques.
Druggability
DruggableYes
Known drugs / candidates0
Small-molecule tractableYes
Antibody tractableNo
EnsemblENSG00000142082
Type I vs Type II discrimination
ScoresLow-confidence (proxy)
R — rupture / Type-I35
C — confounder / Type-II84
A — assay feasibility68
E — evidence strength31
T1DI (composite)5
Specificity differential (R−C)-49.4
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.
Assay & specimen
Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Serum or plasma
Collection tube
Serum separator (gold/red-top, SST) · K2/K3-EDTA (lavender-top)
Method / principle
Sandwich immunoassay (ELISA) — research-grade unless a cleared assay exists
Reagent / substrate
Matched anti-target antibody pair (capture + labeled detection)
Platform
ELISA microplate or multiplex (Luminex/MSD)
Turnaround · availability
Send-out / research · Research-grade (no universal clinical assay)
Literature evidence(2)
- Untargeted metabolomics identified kynurenine as a predictive prognostic biomarker in acute myocardial infarction.Frontiers in immunology · 2022 · PMID 36405744 · doi
- Empagliflozin, an SGLT2 Inhibitor, Reduced the Mortality Rate after Acute Myocardial Infarction with Modification of Cardiac Metabolomes and Antioxidants in Diabetic Rats.The Journal of pharmacology and experimental therapeutics · 2018 · PMID 30552292 · doi